This report provides comprehensive information on the therapeutic development for Open-Angle
Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
The two, pivotal six-month Phase III studies evaluated the safety and efficacy of SimbrinzaA administered twice daily, and enrolled a total of 1,450 patients with open-angle
glaucoma or ocular hypertension who were insufficiently controlled on monotherapy or were already using multiple IOP-lowering medications.
Patients with open-angle
glaucoma and history of exposure to illegal drugs were nearly 20 years younger than glaucoma patients without a drug exposure history (54 years old versus 73 years old).
Yutao Liu, Duke University Medical Center, will investigate gene copy number variants in primary open-angle
Our results suggest that a computer-based imaging tool designed to detect narrowing of the retinal artery calibre, or diameter, could effectively identify those who are most at risk for open-angle
glaucoma," said lead author of the study, Paul Mitchell, from the Centre for Vision Research at the University of Sydney.
This population-based study included participants 55 years of age and older living in a suburb of Rotterdam, who did not have open-angle
glaucoma when the study began between 1991 and 1993.
presented data on a novel drug treatment for primary open-angle
A snapshot of the global therapeutic scenario for Open-Angle
With XFS, chances of developing glaucoma are about six times higher than without XFS, and the severity and prognosis of exfoliation glaucoma is worse than that of primary open-angle
glaucoma (POAG), the routine form of open-angle
The book begins by providing the reader with an overview of the epidemiology of primary open-angle
glaucoma in terms of prevalence and incidence across the world before discussing the risk factors for its development and genetic factors involved in heredity.
During a follow-up screening of these patients at Hopkins, ophthalmologists diagnosed the optic-nerve damage that characterizes primary open-angle
glaucoma in 100 blacks and 32 whites.
OPA-6566, an adenosine A2a receptor agonist, is being developed as an ophthalmic solution to reduce intraocular pressure in open-angle
glaucoma (OAG) or ocular hypertension patients.